NPPA anti-cancer medicine price cuts to take effect from November 9
Revised MRPs reported for 1,225 formulations across 121 drugs, with estimated annual consumer savings of ₹3,502.31 crore
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has capped trade margins on the MRP of 137 anti-cancer drugs, based on the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS) under the Ministry of Health and Family Welfare on October 17, 2026. The revised prices of these drugs will come into effect from November 9, 2026.
As of November 7, 2026, 76 pharma companies have reported revised MRPs for 1,225 anti-cancer formulations, covering 121 drugs. Reductions in MRP have been reported in 1,031 formulations of anti-cancer medicines, with 600 brands reporting reductions of above 50 per cent. The highest reduction reported is 96.45 per cent.
Further, of the 137 identified anti-cancer drugs, 10-15 drugs are yet to be launched in India. However, Trade Margin Rationalisation (TMR) will also apply to these drugs when they are launched.
Following the price reductions coming into effect from November 9, 2026, the estimated annual savings to consumers are expected to be ₹3,502.31 crore.